Date: 2012-05-03
Type of
information: Initiation of the trial
phase: observational study
Announcement: initiation of the trial
Company: Boehringer Ingelheim (Germany)
Product: various antithrombotic therapies, including warfarin, acetylsalicylic acid, Pradaxa® (dabigatran etexilate mesylate) 150mg capsules and Xarelto® (rivaroxaban).
Action
mechanism: anticoagulant agent/oral direct Factor Xa inhibitor
Disease: non-valvular atrial fibrillation
Therapeutic
area: Cardiovascular diseases
Country: 50 countries
Trial
details:
- Boehringer Ingelheim Pharmaceuticals has announced the launch of the GLORIA™-AF Registry Program, the largest prospective observational study in non-valvular atrial fibrillation (NVAF) planned at this time. With a goal of enrolling 56,000 patients, the registry aims to understand the long-term use of antithrombotic treatments to reduce the risk of stroke in patients with NVAF.
- GLORIA-AF will follow newly-diagnosed NVAF patients who are at risk of stroke from 50 countries. The registry, which will be completed in 2020, is designed to gather real-world data on patient demographics, disease characteristics, treatment decisions, and the safety and efficacy of various antithrombotic therapies, including, but not limited to, warfarin, acetylsalicylic acid, Pradaxa® (dabigatran etexilate mesylate) 150mg capsules and Xarelto® (rivaroxaban).
GLORIA-AF will enroll patients from 2,200 sites across a range of clinical settings, including primary care practices, specialist offices, community hospitals, research institutions, outpatient care centers and anticoagulation clinics. To date, sites in the United States, Europe, Latin America and Asia have agreed to participate, providing the potential to identify meaningful information about regional or country-specific differences in patient demographics and treatment decisions.
Latest
news:
Is
general: Yes
